Key result
DTx shows potential to enhance HF management in India by addressing adherence, monitoring, and readmissions.
Why the study?
Indian heart failure registries show high readmissions and mortality, with management challenges including low adherence, inadequate monitoring, and limited longitudinal data.
Does the adoption of digital therapeutics (DTx) improve the management of heart failure in India?
Does the adoption of digital therapeutics (DTx) improve the management of heart failure in India?
Digital therapeutics offer a comprehensive and proactive approach to address the significant challenges of heart failure management in India, including high readmission rates and low medication adherence.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DTx in Indian HF; leaves open RCTs to confirm adherence and readmission benefits before practice change.
Indian heart failure (HF) registries consistently indicate high hospital readmissions and increased mortality rates after HF diagnosis. The challenges of Indian cardiologists in HF management include limited longitudinal data, frequent readmissions, low medication adherence, inadequate monitoring and follow-up, insufficient patient education, and lack of standard guidelines on cardiac rehabilitation. This article outlines the adoption of digital therapeutics (DTx) in HF management as a potential solution to address these challenges. DTx services offer improved medication adherence, early symptom identification, remote vital monitoring, timely intervention, patient education on symptoms, self-awareness, and lifestyle. Overall, DTx for HF comprises a dedicated team of cardiologists, health coaches, care managers, and globally certified connected devices to provide comprehensive and proactive monitoring, personalized coaching and support, behavioral engagement to improve adherence, emergency response system, delivery of medications and diagnostic tests at home, and a dedicated application for caregivers. DTx has the potential to enhance HF management in India.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2023) conducted a review in Heart Failure. Digital Therapeutics (DTx) was evaluated. Digital therapeutics (DTx) has the potential to enhance heart failure management in India by addressing challenges such as low medication adherence, frequent readmissions, and inadequate monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: